Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Staten Biotechnology B.V.

Headquarters: Nijmegen, Netherlands
Website: N/A
Year Founded: 2014
Status: Private

BioCentury | Feb 3, 2022
Product Development

Feb. 2 Quick Takes: Pharming plans global submissions for leniolisib

Plus Novo ends Staten deal, new Pfizer vaccine data coming, Novartis scuttles pan-JAK and more
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

Dutch firm reinvests in CETP inhibitor five years after return from Amgen deal
BioCentury | Dec 21, 2018
Company News

Novo gets option to cardiovascular company Staten

BioCentury | Dec 17, 2018
Company News

Novo gets option to cardiovascular company Staten

BioCentury | Mar 17, 2017
Company News

argenx, Staten Biotechnology deal

BioCentury | Apr 13, 2016
Financial News

Forbion closes third life sciences fund

Items per page:
1 - 6 of 6